Search

Author/Creator Borbath, I

1. 740PFinal results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC. (23rd October 2018)

Authors:
Chiritescu, G; Dumon, K; Verslype, C; Houbiers, G; Peeters, M; Janssens, J; van Daele, D; Laurent, S; Arts, J; Hendrickx, K; Borbath, I; Ferrante, M; Bastin, F M; Goeminne, J-C; van Laethem, J-L; Vanderstraeten, E; Decaestecker, J; van Vaerenbergh, W; Delhougne, B; Van Cutsem, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (13th August 2019)

Authors:
Kulke, M H; Ruszniewski, P; Van Cutsem, E; Lombard-Bohas, C; Valle, J W; De Herder, W W; Pavel, M; Degtyarev, E; Brase, J C; Bubuteishvili-Pacaud, L; Voi, M; Salazar, R; Borbath, I; Fazio, N; Smith, D; Capdevila, J; Riechelmann, R P; Yao, J C
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1846
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018)

Authors:
Javle, M; Kelley, R K; Roychowdhury, S; Weiss, K H; Abou-Alfa, G K; Macarulla, T; Sadeghi, S; Waldschmidt, D; Zhu, A X; Goyal, L; Borad, M; Yong, W P; Borbath, I; El-Khoueiry, A; Philip, P; Moran, S; Ye, Y; Ising, M; Lewis, N; Bekaii-Saab, T
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. O-003Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors. (2nd July 2019)

Authors:
Demols, A; Borbath, I; den Eynde, M Van; Houbiers, G; Peeters, M; Marechal, R; Delaunoit, T; Goeminne, J; Laurent, S; Holbrechts, S; Paesmans, M; Laethem, J Van
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. O-003Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC). (20th June 2018)

Authors:
Chiritescu, G; Dumon, K; Verslype, C; Prenen, H; Houbiers, G; Peeters, M; Janssens, J; Van Daele, D; Laurent, S; Arts, J; Hendrickx, K; Borbath, I; Ferrante, M; Bastin, F; Goeminne, J; Van Laethem, J; Vanderstraeten, E; Decaestecker, J; Van Vaerenbergh, W; Delhougne, B
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019)

Authors:
Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; Ye, Y; Cho, T; Moran, S; Abou-Alfa, G
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗